Noxopharm Ltd. (AU:NOX) has released an update.
Noxopharm Limited, a pioneering Australian biotech firm, has released its Annual Report for the fiscal year ending June 30, 2024, showcasing significant developments in its cancer and inflammation research platforms. The company reports growing external interest in its innovative Sofra™ platform, advancements in their Chroma™ oncology pipeline, and is optimistic about future commercial opportunities and the delivery of benefits to investors.
For further insights into AU:NOX stock, check out TipRanks’ Stock Analysis page.